Rheumatology

Article	Citations
Lupus nephritis: clinical presentations and outcomes in the 21st century	115
Osteosarcopenia: where osteoporosis and sarcopenia collide	111
Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series	100
Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark	98
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study	98
Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors	95
COVID-19 vaccination and antirheumatic therapy	94
Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis	88
Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs	86
Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis	85
Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease	84
A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies	82
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients	77
Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis	74
The safety of JAK-1 inhibitors	73
VEXAS syndrome in a woman	72
Genetics and epigenetics in primary Sjögren’s syndrome	72
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids	70
Rituximab in the treatment of systemic sclerosis–related interstitial lung disease: a systematic review and meta-analysis	68
The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?	68
Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis	67
Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease	67
Sex and gender differences in axial spondyloarthritis: myths and truths	66
Correlation between pain severity and levels of anxiety and depression in osteoarthritis patients: a systematic review and meta-analysis	63
Is fibromyalgia associated with a unique cytokine profile? A systematic review and meta-analysis	61

Classifying and diagnosing systemic lupus erythematosus in the 21st century	59
Treatment of Sjögren’s syndrome: current therapy and future directions	58
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus	58
Glycine increased ferroptosis via SAM-mediated GPX4 promoter methylation in rheumatoid arthritis	56
Rheumatoid arthritis related interstitial lung disease – improving outcomes over 25 years: a large multicentre UK study	53
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study	53
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19	52
Prevalence, incidence and cause-specific mortality of rheumatoid arthritis–associated interstitial lung disease among older rheumatoid arthritis patients	52
Association between environmental air pollution and rheumatoid arthritis flares	52
British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy	50
Clinical course of 602 patients with Takayasu's arteritis: comparison between Childhood-onset versus adult onset disease	49
An association between chronic widespread pain and the gut microbiome	49
Atypical splice-site mutations causing VEXAS syndrome	48
The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis	47
Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice	47
Temporal relationship between osteoarthritis and comorbidities: a combined case control and cohort study in the UK primary care setting	47
Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study	47
Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility	47
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study	46
Socioeconomic status and occurrence of chronic pain: a meta-analysis	45
Telemedicine in rheumatology: a mixed methods study exploring acceptability, preferences and experiences among patients and clinicians	45
Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2)	44
Acute exacerbation of rheumatoid arthritis–associated interstitial lung disease: clinical features and prognosis	44
Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccin	44
A case of psoriatic arthritis triggered by SARS-CoV-2 infection	44
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis	43
VEXAS syndrome: still expanding the clinical phenotype	43
Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic	43
Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease	42
Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions	42
IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts	42
VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy	41
Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis	41
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice	41
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial	40
Childhood Sjögren syndrome: features of an international cohort and application of the 2016 ACR/EULAR classification criteria	40
Treatment strategies in axial spondyloarthritis: what, when and how?	40
Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs	40
Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sjögren’s syndrome	39
Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy	39
Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis	39
Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection	38
Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash	38
All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study	38
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort	38
The impact of education inequality on rheumatoid arthritis risk is mediated by smoking and body mass index: Mendelian randomization study	38
Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study	38
COVID-19 and myositis – unique challenges for patients	37
Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach	37
Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy	37

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition	37
COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries	36
Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis	36
Tele-rheumatology for overcoming socioeconomic barriers to healthcare in resource constrained settings: lessons from COVID-19 pandemic	36
New biomarkers in SLE: from bench to bedside	35
Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study	35
All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study	35
Towards sex-specific osteoarthritis risk models: evaluation of risk factors for knee osteoarthritis in males and females	34
Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis	33
Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study	33
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications	33
Retinal microcirculation abnormalities in patients with systemic sclerosis: an explorative optical coherence tomography angiography study	33
Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica	33
PKM2-dependent glycolysis promotes skeletal muscle cell pyroptosis by activating the NLRP3 inflammasome in dermatomyositis/polymyositis	33
Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis	33
Childhood-onset of primary Sjögren’s syndrome: phenotypic characterization at diagnosis of 158 children	33
A case of VEXAS syndrome manifesting as Kikuchi-Fujimoto disease, relapsing polychondritis, venous thromboembolism and macrocytic anaemia	32
JAK1: Number one in the family; number one in inflammation?	32
JAK1 inhibition and inflammatory bowel disease	32
Treatment targets in SLE: remission and low disease activity state	32
Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study	32
The patient’s perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?	31
Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre	31
Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis	31
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study	31
Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis	30
Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica	30
Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study	30
Patient-based reliability of the Outcome Measures in Rheumatology (OMERACT) ultrasound scoring system for salivary gland assessment in patients with Sjögren’s syndrome	30
Incidence and prevalence of juvenile idiopathic arthritis in the United Kingdom, 2000–2018: results from the Clinical Practice Research Datalink	30
A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients with rheumatoid arthritis	30
Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review	29
New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study	29
Frugoside delays osteoarthritis progression via inhibiting miR-155-modulated synovial macrophage M1 polarization	29
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension	29
Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America	29
Axial spondyloarthritis 10 years on: still looking for the lost tribe	29
Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study	29
A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment	29
Causal relationship of serum nutritional factors with osteoarthritis: a Mendelian randomization study	29
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study	29
Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study	28
Comorbidities (excluding lymphoma) in Sjögren’s syndrome	28
Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients	28
Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series	28
Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis	28
Neutrophil extracellular traps mediate joint hyperalgesia induced by immune inflammation	28
Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease	27
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study	27
Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis	27
Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway	27
A systematic review and meta-analysis of the incidence rate of Takayasu arteritis	27
P105 Prevalence and associated factors of musculoskeletal joint disease in the community setting in Hai district, northern Tanzania	27
High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary care centre in northern India	27
The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease	27
Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants	26
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review	26
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	26
Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search	26
Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis	26
Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER)	26
Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis	26
Plasma proteomics identifies CRTAC1 as a biomarker for osteoarthritis severity and progression	25
Current and emerging biological therapy in adult-onset Still’s disease	25
Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)	25
Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments	25
The association of smoking with immunoglobulin G4–related disease: a case–control study	25
Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis	25
How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies	25
Dissecting the clinical heterogeneity of adult-onset Still’s disease: results from a multi-dimensional characterization and stratification	25
Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study	25
Endotypes of primary osteoarthritis identified by plasma metabolomics analysis	25
Multi-energy photon-counting computed tomography versus other clinical imaging techniques for the identification of articular calcium crystal deposition	25
Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren’s syndrome: results from a harmonized dataset (1981–2021)	25
Joint anatomy in axial spondyloarthritis: strong associations between sacroiliac joint form variation and symptomatic disease	25
Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases	24
Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study	24
Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study	24
Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study	24
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes	24

Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?—observations from the UK JSLE Cohort Study	24
Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA	24
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients	24
Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response	24
Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout	23
Survival and associated comorbidities in inclusion body myositis	23
Quantitative nailfold capillaroscopy—update and possible next steps	23
Consensus-based recommendations for the management of juvenile systemic sclerosis	23
Defining cardiac involvement in idiopathic inflammatory myopathies: a systematic review	23
Deep learning algorithms for magnetic resonance imaging of inflammatory sacroiliitis in axial spondyloarthritis	23
Behçet’s-like adverse event or inaugural Behçet’s disease after SARS-CoV-2 mRNA-1273 vaccination?	23
Vitamin D receptor gene polymorphisms and osteoarthritis: a meta-analysis	23
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies	23
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study	23
The impact of COVID-19 on rheumatology practice across Africa	23
Perturbations of the gut microbiome in anti-CCP positive individuals at risk of developing rheumatoid arthritis	23
Are neutrophil extracellular traps the link for the cross-talk between periodontitis and rheumatoid arthritis physiopathology?	23
US rheumatologists’ beliefs and knowledge about biosimilars: a survey	23
Non-radiographic versus radiographic axSpA: what’s in a name?	23
Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China	23
A dysregulated interleukin-18–interferon-γ–CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis	23
Oxidative stress-induced senescence mediates inflammatory and fibrotic phenotypes in fibroblasts from systemic sclerosis patients	22
Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic	22
Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India	22
Monocytic MDSCs skew Th17 cells toward a pro-osteoclastogenic phenotype and potentiate bone erosion in rheumatoid arthritis	22
Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study)	22
AI am a rheumatologist: a practical primer to large language models for rheumatologists	22
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)	22
Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus	22
Prevalence of anxiety and depression in patients with rheumatoid arthritis before and during the COVID-19 pandemic	22
Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to anakinra	22
Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience	22
Feasibility of online home spirometry in systemic sclerosis–associated interstitial lung disease: a pilot study	22
Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis	22
Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study	22
Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review	22
Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models	22
Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma	22
Mortality in patients with primary Sjögren’s syndrome: a systematic review and meta-analysis	22
STAT3 phosphorylation inhibition for treating inflammation and new bone formation in ankylosing spondylitis	21
Regulatory T cell/Th17 balance in the pathogenesis of paediatric Behçet disease	21
Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study	21
Interferon-stimulated GTPases in autoimmune and inflammatory diseases: promising role for the guanylate-binding protein (GBP) family	21
Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus	21
Genetics and the axial spondyloarthritis spectrum	21
Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results	21
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis	21
Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual	21
Asporin regulated by miR-26b-5p mediates chondrocyte senescence and exacerbates osteoarthritis progression via TGF-β1/Smad2 pathway	21
An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus	21
Potential efficacy of dendritic cell immunomodulation in the treatment of osteoarthritis	21
Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort	21
COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis	21
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data	21
A novel semi-automated classifier of hip osteoarthritis on DXA images shows expected relationships with clinical outcomes in UK Biobank	21
Genome-wide association study on Northern Chinese identifies KLF2, DOT1L and STAB2 associated with systemic lupus erythematosus	21
Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis	21
Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial	21
Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis	21
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort	21
Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis	21
Association of particulate matter with autoimmune rheumatic diseases among adults in South Korea	20
Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss	20
New developments in Sjogren’s syndrome	20
Towards developing diagnostic criteria for early knee osteoarthritis: data from the CHECK study	20
The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids	20
Causal association of adipokines with osteoarthritis: a Mendelian randomization study	20
Fully automated opportunistic screening of vertebral fractures and osteoporosis on more than 150 000 routine computed tomography scans	20
P208 A retrospective survey of arthritis among inpatients at a consultant hospital in Northern Tanzania from 2017 to 2019	20
A predictive clinical-radiomics nomogram for diagnosing of axial spondyloarthritis using MRI and clinical risk factors	20
Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study	20
Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients	20
Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients	20
Peripheral blood mononuclear cells are hypomethylated in active rheumatoid arthritis and methylation correlates with disease activity	20
Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study	20
The impact of social determinants of health on the presentation, management and outcomes of systemic lupus erythematosus	20
Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study	20
Histopathology, salivary flow and ultrasonography of the parotid gland: three complementary measurements in primary Sjögren’s syndrome	20
Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies	20
Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry	20
Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy	20
Fertility and pregnancy outcomes in women with spondyloarthritis: a systematic review and meta-analysis	20
Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines	20
Advanced neural networks for classification of MRI in psoriatic arthritis, seronegative, and seropositive rheumatoid arthritis	20
Ultrasonography in the diagnosis and follow-up of giant cell arteritis	19
Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease	19
Pulmonary involvement in primary systemic vasculitides	19
A Case of polychondritis-onset refractory organizing pneumonia with cytopaenia diagnosed as VEXAS syndrome: the disease course of 7 years	19
Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study	19
Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis	19
Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)	19
CCL2 produced by CD68+/CD163+ macrophages as a promising clinical biomarker of microscopic polyangiitis-interstitial lung disease	19
Metformin attenuates osteoarthritis by targeting chondrocytes, synovial macrophages and adipocytes	19
Successful treatment with azacitidine in VEXAS syndrome with prominent myofasciitis	19
Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre	19